Evidence map›Paper›PMID 32044178›Full record

ArticleJournal of dermatological science2020

Diet-induced obesity exacerbates imiquimod-mediated psoriasiform dermatitis in anti-PD-1 antibody-treated mice: Implications for patients being treated with checkpoint inhibitors for cancer.

Sebastian Yu, Xuesong Wu, Zhenrui Shi, Mindy Huynh, Prasant Kumar Jena, Lili Sheng, Yan Zhou, Dan Han, Yu-Jui Yvonne Wan, Samuel T Hwang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of dermatological science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Use of Clinical Public Databases in Hidradenitis Suppurativa Research.Interactive journal of medical research · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Extracts fromHeliyon · 2023
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Experimental research in topical psoriasis therapy (Review).Experimental and therapeutic medicine · 2021
    Review
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Sebastian YuGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Dermatology, University of California, Davis, Sacramento, CA, USA; Department of Dermatology, Kaohsiung Medical University Hospital, and Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Xuesong WuDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Zhenrui ShiDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Mindy HuynhDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Prasant Kumar JenaDepartment of Medical Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA, USA.
Lili ShengDepartment of Medical Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA, USA.
Yan ZhouDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Dan HanDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Yu-Jui Yvonne WanDepartment of Medical Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA, USA.
Samuel T HwangGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Dermatology, University of California, Davis, Sacramento, CA, USA. Electronic address: sthwang@ucdavis.edu.
University of California, Davis · USUniversity of California Davis Medical Center · USKaohsiung Medical University · TW

Funding

The Role of Probiotic Bifidobacteria and Bile Acid Metabolism in CarcinogenesisU01CA179582 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MILLS, DAVID ANDREW, SLUPSKY, CAROLYN · 2014 to 2018
$2.8M
Liver Cancer Therapy by MiR-22 and Its InducersR01CA222490 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI WAN, YU-JUI YVONNE · 2018 to 2023
$2.1M
NCI NIH HHS R01 CA222490NCI NIH HHS U01 CA179582
6 · The paper itself

Abstract

backgroundAn ever-increasing number of cancer patients are being treated with checkpoint inhibitors such as anti-PD-1 antibodies, and a small percentage of these patients develop a psoriasis-like skin eruption or severe flares of prior psoriasis.

objectiveWe investigated the role of obesity in immune checkpoint inhibitors-exacerbated psoriasiform eruption.

methodsWe fed female C57BL/6 mice a so-called Western diet (WD) or a control diet (CD). Imiquimod (IMQ) was applied topically on ears for 5 consecutive days to induce psoriasiform dermatitis (PsD). Psoriasis-related markers were examined by quantitative real-time PCR. Then we induced PsD in WD- and CD-fed mice in the presence or absence of systemic treatment of anti-PD-1 antibodies to examine if obese mice are more susceptible to anti-PD-1 related PsD than lean mice.

resultsWD-fed mice showed higher baseline mRNA expression levels of psoriasis-associated cytokines such as IL-17, S100A8, and S100A9 compared to mice fed with CD. Furthermore, WD-fed mice had more γδ low (GDL) T cells in the whole skin and higher expression of PD-1 on GDL T cells than CD-fed mice. WD-fed mice receiving anti-PD-1 had more prominent ear swelling than lean mice receiving anti-PD-1 during the 5-day IMQ course (2-fold increase, P < 0.0001 on day 5).

conclusionWD-induced obesity enhances IMQ-induced psoriasiform inflammation. The finding that WD-fed mice have a more dramatic response to anti-PD-1 than lean mice in terms of IMQ-induced ear swelling suggests that obesity could be a risk factor in the development of psoriasiform eruption during anti-PD-1 therapy.

Indexed as

AnimalsDiet, WesternDisease Models, AnimalFemaleHumansImiquimodImmune Checkpoint InhibitorsMiceNeoplasmsObesityProgrammed Cell Death 1 ReceptorPsoriasisRisk FactorsSkinSymptom Flare UpImiquimodImmune Checkpoint InhibitorsPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorHigh-fat dietImmune checkpointPsoriasisSugarWestern diet

Identifiers

PMID32044178
PMCPMC7469262
OpenAlexW3002958431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.